Gapping up
In reaction to strong earnings/guidance:
- VIVE +27.5%, AEZS +15%, CDNA +14.9%, CHMA +14.3%, (also has reached agreement with the FDA on the design of a new Phase 3 clinical trial for its octreotide capsules product candidate, Mycapssa), HEAR +11.9%, ANW +10.8%, TTD +7.5%, AMRS +5.9%, CWH +5.7%, EPAY +4.9%, CAPR +4.7%, NDLS +3.8%, CATB +2.5%, CYTX +2.4%, WPM +1.6%, CRSP +1.1%, ZSAN +1.1%
Other news:
- DRYS +4.9% (announces agreement to conduct a private placement and subsequent rights offering at $2.75/share; terminates common stock purchase agreement with Kalani Investments)
- TOPS +41.8% (following stock offering news from peer DryShips (DRYS))
- CUDA +3.9% (to Join S&P SmallCap 600)
- XXII +3.2% (ongoing volatility)
- STX +3% (ValueAct Capital discloses 7.2% active stake after increasing position to 21 mln shares (showed 9.54 mln share position at end of Q1))
- KURA +2.3% (prices offering of 7.7 mln shares of common stock at $6.50 per share)
- EFII +2% ( files to delay its 10-Q; updates Q2 expectations excluding any adjustments from ongoing assessment/audit review)
- ETSY +0.9% (Pres/CEO disclosed purchase of 64000 shares worth approx $1 mln)
Analyst comments:
- PM +0.9% (upgraded to Hold at SBG Securities)
- SBBP +0.8% (initiated with an Outperform at Oppenheimer; $12 tgt)